P71 Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one centre’s experience
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.213
Abstract: Introduction Mepolizumab is an anti-interleukin-5 monoclonal antibody shown to reduce asthma exacerbations in adults and adolescents with severe eosinophilic asthma.1 The Scottish Medicines Commission has accepted it for restricted use in adults as an add-on… read more here.
Keywords: asthma eligible; severe eosinophilic; mepolizumab; eosinophilic asthma ... See more keywords